Sign In
Buy ANIX
$3.42
-0.140 (-3.93%)
At Close: Jul 31, 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
08:55am, Tuesday, 07'th Apr 2026
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in 74% of participants in Phase 1 clinical trial Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
09:10am, Monday, 06'th Apr 2026
SAN JOSE, Calif., April 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ann
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
08:50am, Wednesday, 01'st Apr 2026
Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants SAN JOSE, Calif., April 1, 202
Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-cel trial status SAN JOSE, Calif., March 30, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
10:38am, Thursday, 12'th Mar 2026
SAN JOSE, Calif., March 12, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platform Expands global intellectual property coverage in markets with increasing breast cancer incidence rates and
Presentation to Review Ovarian Cancer CAR-T Survival Observations and Dose Escalation, as well as Final Phase 1 Breast Cancer Vaccine Data SAN JOSE, Calif., March 2, 2026 /PRNewswire/ -- Anixa Bioscie
Dr. Conejo-Garcia is the co-inventor of Anixa's FSHR-mediated CAR-T technology SAN JOSE, Calif., Feb. 23, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi
Multiple patients substantially exceed expected survival at low dose levels; absence of dose-limiting toxicities supports escalation to doses up to 100x higher Trial expansion reflects growing confide
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
07:31am, Monday, 09'th Feb 2026
Anixa Biosciences, Inc. (NASDAQ: ANIX) on Monday provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol
SAN JOSE, Calif., Feb. 2, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today anno
Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and
January 21, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Anixa Biosciences, Inc. (NASDAQ: ANIX) titled, “Anixa's T
Anixa Biosciences Inc (NASDAQ:ANIX) Short Interest Update
05:00am, Monday, 19'th Jan 2026
Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 1,002,532 shares,
Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals
05:34pm, Monday, 12'th Jan 2026
Guru Stock PicksJerome Dodson has made the following transactions:Reduce in ORLY by 3%Sold out in BLDRAdd in NTRA by 2.49%New position in INSMTweedy Browne Inte
